Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Aflac (AFL) Launches Critical Illness Product In U.S. Unit

Published 11/13/2018, 10:22 PM
Updated 07/09/2023, 06:31 AM

Aflac Inc. (NYSE:AFL) has launched a new insurance product named Lump Sum Critical Illness Insurance in its U.S. segment.

The critical illness product has been redesigned to include new riders and a wider range of benefits for offering customers a holistic approach to recovery and care.

This product will be an addition to the company’s existing bouquet sold under direct to consumer portfolio. Other Aflac plans available directly to consumers include cancer, accident, life, dental and specified health event. For 2019, the company has planned to introduce more products in this category.

This product will be available in the voluntary insurance market, which can be easily accessed by millions of Americans working outside the traditional workplace as freelancers, contractors, self-employed solopreneurs and those in startups.

The critical illness product carries features like lump sum payment, building benefit, hospitalization rider and a new event recovery rider. The policy is currently available across nine states in the United States. It will also be present in 10 additional states by this year-end. Remaining states will join the line-up in 2019.

The company’s U.S. segment continues to perform strongly as is evident from a revenue CAGR of 3% from 2008-2017, which sustained through the first nine months of 2018 with revenues up 2.5%. The company has undertaken a number of growth initiatives in this segment such as the adoption of Everwell and One Pay Day for increased penetration, delivery of value-added services and stronger client retentionand investment in administrative capabilities. These initiatives should drive the company’s top-line growth. In 2018, the company’s 3-5% sales growth is expected to result in 2-3% growth in earned premiums.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

In a year’s time, the stock has gained 5.3% versus the industry’s decline of 4.2%.

Aflac carries a Zacks Rank # 3 (Hold). Some better-ranked stocks in the space are AMERISAFE, Inc. (NASDAQ:AMSF) , Employers Holdings Inc. (NYSE:EIG) and Unum Group (NYSE:UNM) , each carrying a Zacks Rank #2 (Buy). You can seethe complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

AMERISAFE and Unum’s earnings surpassed estimates in three of the four reported quarters, the average positive surprise being 15.4% and 3.31%, respectively. While Employers Holdings’ metric beat estimates in each of the four reported quarters, the average being 77.83%.

3 Medical Stocks to Buy Now

The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.

So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.

See them today for free >>





AMERISAFE, Inc. (AMSF): Free Stock Analysis Report

Unum Group (UNM): Free Stock Analysis Report

Aflac Incorporated (AFL): Free Stock Analysis Report

Employers Holdings Inc (EIG): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.